Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.34+0.02 (+0.86%)
Close on Nov 18, 2026Market cap $138.28MP/E –Yield –
Protara Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Protara Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$76.79M. For fiscal 2025 it was -$64.55M. The highest annual figure on record is -$7.12M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$64.55M | – |
| FY2024 | Dec 31, 2024 | -$49.15M | – |
| FY2023 | Dec 31, 2023 | -$43.61M | – |
| FY2022 | Dec 31, 2022 | -$67.06M | – |
| FY2021 | Dec 31, 2021 | -$47.49M | – |
| FY2020 | Dec 31, 2020 | -$34.44M | – |
| FY2019 | Dec 31, 2019 | -$7.83M | – |
| FY2018 | Dec 31, 2018 | -$21.37M | – |
| FY2017 | Dec 31, 2017 | -$30.36M | – |
| FY2016 | Dec 31, 2016 | -$28.71M | – |
| FY2015 | Dec 31, 2015 | -$20.87M | – |
| FY2014 | Dec 31, 2014 | -$7.58M | – |
| FY2013 | Dec 31, 2013 | -$7.12M | – |
| FY2012 | Dec 31, 2012 | -$8.00M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.73M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.16M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.35M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.43M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.53M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.62M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.37M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.59M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.99M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.48M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.87M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.17M | – |
See a number that looks wrong?